StockData
CVRx, Inc. logo

CVRx, Inc. (CVRX) company profile

CVRXNasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 8/3091% below fair value
$0.61−0.00 (-0.33%)

Close on Nov 17, 2026Market cap $16.28MP/E –Yield –

About CVRx

Surgical & Medical Instruments & Apparatus, SIC 3841

CVRx is a commercial-stage medical device enterprise that designs, manufactures, and markets minimally invasive neuromodulation therapies for cardiovascular disease. The company's core product is Barostim, an implantable system featuring a pulse generator, a stimulation lead, and a wireless clinician programmer. It operates by delivering electrical pulses to carotid artery baroreceptors to counteract autonomic nervous system imbalances and ease symptoms of heart failure with reduced ejection fraction. Target customers primarily include hospitals, heart failure specialists, cardiologists, and surgeons.

The business commercializes its systems directly to healthcare facilities across the United States and Germany, while engaging independent distributors in Austria, Spain, and additional European territories. Its clinical research and trial footprint extends across multiple nations, including the United States, Germany, Italy, France, Canada, and the United Kingdom. Corporate headquarters are not stated in the provided text.

Summary of the business section of CVRx's latest annual report, written by StockData.

Company profile

Company

Legal name
CVRx, Inc.
Founded
2001
Headquarters
Minneapolis, MN
Address
9201 West Broadway Avenue, Suite 650 55445
Phone
(763) 416-2850
Employees
223, Dec 31, 2025
Industry
Surgical & Medical Instruments & Apparatus
Incorporated in
Delaware
Fiscal year ends
December 31
Auditor
GRANT THORNTON LLP, Minneapolis, Minnesota

Stock & identifiers

Ticker
CVRX
Exchange
Nasdaq
IPO date
Jul 1, 2021
Shares outstanding
27M, Jul 30, 2026
Public float
$112.40M, Jun 30, 2025
Filer category
Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
SEC CIK
1235912
CUSIP
126638105
ISIN
US1266381052
FIGI
BBG001B56NX0
Share class FIGI
BBG001TJ3M57
EIN
00-0000000

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
Kevin HykesPRES & CEO, Director284,237
John LandryChief Financial Officer41,433
Brent BinkowskiCHIEF OPERATING OFFICER56,514
Philip B. AdamsonChief Medical Officer61,578
Gregory MorrisonCHIEF HUMAN RESOURCES OFFICER34,000
Jared OasheimCHIEF FINANCIAL OFFICER96,703
Paul VerrastroCHIEF MKTG & STRAT OFFICER60,551
Robert Allen JohnChief Revenue Officer86,036
Hill, Mitch C.Director8,720
Martha ShadanDirector8,720
Mudit K. JainDirector994,553
Joseph P. SlatteryDirector39,365
Michael D. DaleDirector29,005
Kirk G. NielsenDirector1,918,854
Kevin J. BallingerDirector8,720

Executive compensation, fiscal 2025

Summary compensation table from the latest proxy statement

ExecutiveSalaryStock awardsOption awardsIncentive payOtherTotalvs. prior year
Kevin Hykes
President and Chief Executive Officer
$660.53K$1.27M$1.52M$444.49K$13.80K$3.91M-55%
Robert John
Chief Revenue Officer
$485.31K$712.80K$389.47K$161.00K$13.80K$1.76M+18%
Philip Adamson
Chief Medical Officer
$549.54K$259.20K$307.48K$231.13K$13.80K$1.36M–

Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.

IPO

From the final prospectus (Form 424B4) and the first day of trading

Offering

Type
Initial public offering
Final prospectus filed
Jul 1, 2021
Securities offered
7,000,000
Exchange
Nasdaq
First trading day
Jun 30, 2021
First-day close
$28.00
Lock-up ends (est.)
Dec 27, 2021

Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.

Employees

Headcount reported in annual reports

“As of December 31, 2025, we had 223 employees worldwide, all of which were employed on a full-time basis.”

Corporate history

Events identified from SEC filings

See a number that looks wrong?